ArticleArXiv2025
DruGagent: Multi-Agent Large Language Model-Based Reasoning for Drug-Target Interaction Prediction.
Article in ArXiv, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advancements in large language models (LLMs) allow them to address diverse questions using human-like interfaces. Still, limitations in their training prevent them from answering accurately in scenarios that could benefit from multiple perspectives. Multi-agent systems allow the resolution of questions to enhance result consistency and reliability. While drug-target interaction (DTI) prediction is important for drug discovery, existing approaches face challenges due to complex biological systems and the lack of interpretability needed for clinical applications. DrugAgent is a multi-agent LLM system for DTI prediction that combines multiple specialized perspectives with transparent reasoning. Our system adapts and extends existing multi-agent frameworks by (1) applying coordinator-based architecture to the DTI domain, (2) integrating domain-specific data sources, including ML predictions, knowledge graphs, and literature evidence, and (3) incorporating Chain-of-Thought (CoT) and ReAct (Reason+Act) frameworks for transparent DTI reasoning. We conducted comprehensive experiments using a kinase inhibitor dataset, where our multi-agent LLM method outperformed the non-reasoning multi-agent model (GPT-4o mini) by 45% in F1 score (0.514 vs 0.355). Through ablation studies, we demonstrated the contributions of each agent, with the AI agent being the most impactful, followed by the KG agent and search agent. Most importantly, our approach provides detailed, human-interpretable reasoning for each prediction by combining evidence from multiple sources - a critical feature for biomedical applications where understanding the rationale behind predictions is essential for clinical decision-making and regulatory compliance. Code is available at https://anonymous.4open.science/r/DrugAgent-B2EA.
Identifiers
40297237PMC12036430What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.